About Aspartoacylase
Aspartoacylase (ASPA) is a protein
from Homo sapiens identified by UniProt accession
P45381, 313 residues long.
MolForge cross-references it against 0 known binders and
418 disease associations.
Target properties
| Protein name | Aspartoacylase |
|---|
| UniProt accession | P45381 |
|---|
| Gene | ASPA |
|---|
| Organism | Homo sapiens |
|---|
| Length | 313 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (418)
Diseases linked to this target (Open Targets).
- Canavan disease · score 0.85
- genetic disorder · score 0.54
- mild Canavan disease · score 0.52
- severe Canavan disease · score 0.37
- Abnormality of metabolism/homeostasis · score 0.27
- pathological myopia · score 0.26
- Intellectual disability · score 0.11
- Fraser syndrome · score 0.11
- vital capacity · score 0.10
- spinocerebellar ataxia type 35 · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P45381-F1 | alphafold | PREDICTED | 96.06 | — |
Amino-acid sequence (313 residues)
MTSCHIAEEH IQKVAIFGGT HGNELTGVFL VKHWLENGAE IQRTGLEVKP FITNPRAVKK CTRYIDCDLN RIFDLENLGK KMSEDLPYEV RRAQEINHLF GPKDSEDSYD IIFDLHNTTS NMGCTLILED SRNNFLIQMF HYIKTSLAPL PCYVYLIEHP SLKYATTRSI AKYPVGIEVG PQPQGVLRAD ILDQMRKMIK HALDFIHHFN EGKEFPPCAI EVYKIIEKVD YPRDENGEIA AIIHPNLQDQ DWKPLHPGDP MFLTLDGKTI PLGGDCTVYP VFVNEAAYYE KKEAFAKTTK LTLNAKSIRC CLH
Explore Aspartoacylase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets